The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo
Authors:
- A BellucciA Bellucci
- F CasamentiFCF Casamenti
- 1 April 2003
- journal article
- Published by Elsevier in Neuroscience
- Vol. 117 (4) , 909-919
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's diseaseJournal of Neuroscience Research, 1999
- Involvement of p38 mitogen‐activated protein kinase in lipopolysaccharide‐induced iNOS and COX‐2 expression in J774 macrophagesImmunology, 1999
- MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASESAnnual Review of Neuroscience, 1999
- Interleukin-1β Regulation of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Involves the p42/44 and p38 MAPK Signaling Pathways in Cardiac MyocytesHypertension, 1999
- RofecoxibDrugs, 1999
- Indomethacin Reverses the Microglial Response to Amyloid β-ProteinNeurobiology of Aging, 1998
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease ProgressionBrain Pathology, 1998
- Cognitive functions of cortical acetylcholine: toward a unifying hypothesisBrain Research Reviews, 1997
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982